We are international
Donate
• myeloma tv TEXT SIZE   

Velcade Videos
    next      view all

Research
12.07.10   Webcasts from the American Society of Hematology Annual Meeting in 2010 about VELCADE Clinical Trials

06.08.10   2010 ASCO Annual Meeting VELCADE Webcasts

01.04.08   Dr. Harousseau - VELCADE/Dexamethasone (Vel/D) Versus VAD as Induction Treatment Prior to Autologous Stem Cell Transplantion (ASCT) in Newly Diagnosed Multiple Myeloma (MM): Updated Results of the IFM 2005/01 Trial
Jean Luc Harousseau, MD
Hematologie Clinique
CHU Hotel Dieu
Nantes, France
Member, IMF Board of Scientific Advisors

01.04.08   Dr. Reeder - Phase II Trial of Myeloma Induction Therapy with Cyclophosphamide, Bortezomib, and Dexamethasone (Cybor-D): Improved Response over Historical Lenalidomide-Dexamethasone Controls
Craig B. Reeder, MD
Mayo Clinic
Scottsdale, Arizona

01.02.08   Dr. Davies - The Combination of Velcade, Idarubicin and Melphalan (VIM) Demonstrates Significant Clinical Activity in Relapsed/Refractory Myeloma Patients
Faith E. Davies, MD
The Royal Marsden NHS Foundation Trust
Sutton, Surrey, UK
Member, IMF Board of Scientific Advisors

12.25.07   Dr. Jagannath - Updated Survival Analyses after Prolonged Follow-Up of the Phase 2, Multicenter CREST Study of Bortezomib in Relapsed or Refractory Multiple Myeloma
Sundar Jagannath, MD
St. Vincent's Comprehensive Cancer Center
New York, NY
Member, IMF Board of Scientific Advisors

12.23.07   Dr. Bladé - The Prolonged Time to Progression with Pegylated Liposomal Doxorubicin + Bortezomib Versus Bortezomib Alone in Relapsed or Refractory Multiple Myeloma Is Unaffected by Extent of Prior Therapy or Previous Anthracycline Exposure
Joan Bladé, MD
Hospital Clinic
Hematology
Barcelona, Spain
Member, IMF Board of Scientific Advisors

12.23.07   Dr. Palumbo - Bortezomib, Pegylated-Lyposomal-Doxorubicin and Dexamethasone Followed by Melphalan 100 mg/m in Elderly Newly Diagnosed Patients: An Interim Analysis
Antonio Palumbo, MD
Ospedale Molinette
Torino, Italy
Member,IMF Board of Scientific Advisors

12.22.07   Dr. Jagannath - A Phase II Study of Bortezomib (Velcade®), Cylophosphamide (Cytoxan®), Thalidomide (Thalomid®) and Dexamethasone as First-Line Therapy for Multiple Myeloma
Sundar Jagannath, MD
St. Vincent's Comprehensive Cancer Center
New York, New York
Member, IMF Board of Scientific Advisors

12.20.07   Dr. San Miguel - A Phase 3 Study Comparing BortezomibMelphalanPrednisone (VMP) with MelphalanPrednisone (MP) in Newly Diagnosed Multiple Myeloma.
Dr. Jesús San Miguel
Hospital Clinico Universitario
Universidad de Salamanca
Salamanca, Spain
Member, IMF Board of Scientific Advisors

    next      view all